Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

METMEL

Financiado

Cerrado

Long range acting drivers of premetastatic niches in melanoma

Melanoma is the cancer with the fastest rising incidence world-wide, and although recent therapies can achieve unprecedented response rates, a significant fraction of patients still succumb to metastatic lesions. Key pending quest... ver más

13/11/2021

FUNDACION SECTOR P...

170K€

Presupuesto del proyecto: 170K€

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-13

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACION SECTOR PUBLICO EST...

170.12K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

METALERT-STOP Imaging characterizing and targeting metastatic niches in m... 2M€ Cerrado

FORCE Imaging the Force of Cancer 7M€ Cerrado

PID2020-117621RB-I00 VISUALIZACION Y TRATAMIENTO DE LOS NICHOS METASTASICOS EN EL... 500K€ Cerrado

METANICHE Regulation of bone metastases by age associated angiocrine s... 1M€ Cerrado

BMDCMET Innate and adaptive immune cell contribution to the pre meta... 184K€ Cerrado

MetaMelNiche Deciphering the melanoma-niche cell interplay to identify no... 196K€ Cerrado

Duración del proyecto: 55 meses Fecha Inicio: 2017-03-14
Fecha Fin: 2021-11-13

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Presupuesto del proyecto 170K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Melanoma is the cancer with the fastest rising incidence world-wide, and although recent therapies can achieve unprecedented response rates, a significant fraction of patients still succumb to metastatic lesions. Key pending questions in the field are the mechanisms underlying the inherent metastatic behaviour or melanoma, whereby seemingly thin primary lesions (≥2 mm in depth) bear high risk of dissemination to proximal lymph nodes and ultimately, to distal sites. A dynamic crosstalk has been proposed to be established between melanoma cells and the lymphatic vasculature at tumour-draining lymph nodes, favouring an immune-permissive lymphovascular niche. However, whether (and how) these lymphovascular interactions occur at distal sites is unclear. The Soengas group has generated unique Lymphoreporter melanoma mouse models for non-invasive and whole body imaging of tumour progression. These lymphoreporters demonstrated that primary melanomas induce neo-lymphangiogenesis at distal pre-metastatic sites, already from very early stages of the disease, before dissemination occurs. Proteomic analyses were then performed to identify factors in the melanoma secretome that could drive these long range-acting effects and subsequently filtered these proteins for novelty (i.e. no previous link to melanoma and lymphangiogenesis). Here I will focus on the top-ranking factors in this screening. In particular, I will define the impact of these newly-identified melanoma secreted factors on tumour progression and metastasis, focusing on key components of the lymphovascular niche (i.e. on the crosstalk of tumour- vasculature-immune system). Secondly, I will assess the impact of these genes as prognostic biomarkers and indicators of response to clinically-relevant treatments. These studies will be performed in collaboration with dermatologists, pathologists and oncologist to define the physiological relevance of our work.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores